Compile Data Set for Download or QSAR
Report error Found 151 Enz. Inhib. hit(s) with all data for entry = 316
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM407(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DatapH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM415(N-(4-{[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyp...)
Affinity DatapH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM452(CHEMBL168525 | 4-({6-[2-(4-aminophenyl)ethyl]-4-hy...)
Affinity DataIC50: 1.30nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM452(CHEMBL168525 | 4-({6-[2-(4-aminophenyl)ethyl]-4-hy...)
Affinity DataIC50: 1.30nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM410(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 1.5nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM410(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 1.5nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM457(CHEMBL172271 | 3-({2-tert-butyl-4-[(ethylsulfamoyl...)
Affinity DataIC50: 1.70nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM457(CHEMBL172271 | 3-({2-tert-butyl-4-[(ethylsulfamoyl...)
Affinity DataIC50: 1.70nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM398(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 1.80nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM417(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 1.90nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM428(N-(5-tert-butyl-4-{[4-hydroxy-2-oxo-6-(2-phenyleth...)
Affinity DataIC50: 1.90nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409134(CHEMBL171434)
Affinity DataIC50: 1.90nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409145(CHEMBL169878)
Affinity DataIC50: 1.90nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM441(5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyphenyl)e...)
Affinity DataIC50: 2nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409125(CHEMBL169256)
Affinity DataIC50: 2nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM414(CHEMBL168369 | N-[5-tert-butyl-4-({4-hydroxy-6-[2-...)
Affinity DataIC50: 2.10nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM414(CHEMBL168369 | N-[5-tert-butyl-4-({4-hydroxy-6-[2-...)
Affinity DataIC50: 2.10nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM431(5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyphenyl)e...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM446(5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyphenyl)e...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM454(4-({6-[2-(4-aminophenyl)ethyl]-4-hydroxy-2-oxo-6-(...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM403(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409138(CHEMBL171229)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409170(CHEMBL86226)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM472(CHEMBL2110204 | 5-tert-butyl-4-{[(6S)-4-hydroxy-6-...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM436(5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyphenyl)e...)
Affinity DataIC50: 2.40nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409127(CHEMBL170162)
Affinity DataIC50: 2.40nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM405(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 2.60nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM406(CHEMBL354867 | N-[5-tert-butyl-4-({4-hydroxy-6-[2-...)
Affinity DataIC50: 2.60nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM406(CHEMBL354867 | N-[5-tert-butyl-4-({4-hydroxy-6-[2-...)
Affinity DataIC50: 2.60nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM405(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 2.60nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM396(CHEMBL38268 | 3-[(4-amino-2-tert-butyl-5-methylphe...)
Affinity DataIC50: 2.70nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM426(N-(5-tert-butyl-4-{[4-hydroxy-2-oxo-6-(2-phenyleth...)
Affinity DataIC50: 3nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM449(5-tert-butyl-4-{[4-hydroxy-2-oxo-6-(2-phenylethyl)...)
Affinity DataIC50: 3nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409129(CHEMBL354829)
Affinity DataIC50: 3nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM426(N-(5-tert-butyl-4-{[4-hydroxy-2-oxo-6-(2-phenyleth...)
Affinity DataIC50: 3nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM458(CHEMBL169074 | 3-({2-tert-butyl-4-[(ethylsulfamoyl...)
Affinity DataIC50: 3.30nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM458(CHEMBL169074 | 3-({2-tert-butyl-4-[(ethylsulfamoyl...)
Affinity DataIC50: 3.30nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM459(6-Alkyl-5,6-Dihydropyran-2-one 22 | 5-tert-butyl-4...)
Affinity DataIC50: 3.40nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM459(6-Alkyl-5,6-Dihydropyran-2-one 22 | 5-tert-butyl-4...)
Affinity DataIC50: 3.40nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM412(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 3.5nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM427(CHEMBL353086 | N-(5-tert-butyl-4-{[4-hydroxy-2-oxo...)
Affinity DataIC50: 3.5nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM438(CHEMBL171786 | 5-tert-butyl-4-({4-hydroxy-6-[2-(4-...)
Affinity DataIC50: 3.5nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM438(CHEMBL171786 | 5-tert-butyl-4-({4-hydroxy-6-[2-(4-...)
Affinity DataIC50: 3.5nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM427(CHEMBL353086 | N-(5-tert-butyl-4-{[4-hydroxy-2-oxo...)
Affinity DataIC50: 3.5nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM412(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 3.5nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM418(N-[5-tert-butyl-4-({6-cyclopropyl-4-hydroxy-6-[2-(...)
Affinity DataIC50: 3.60nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM420(CHEMBL288033 | 3-[(4-amino-2-tert-butyl-5-methylph...)
Affinity DataIC50: 3.60nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM425(CHEMBL351155 | N-(5-tert-butyl-4-{[4-hydroxy-2-oxo...)
Affinity DataIC50: 3.60nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM447(5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyphenyl)e...)
Affinity DataIC50: 3.60nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM456(3-({2-tert-butyl-4-[(dimethylsulfamoyl)amino]-5-me...)
Affinity DataIC50: 3.60nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
Displayed 1 to 50 (of 151 total ) | Next | Last >>
Jump to: